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Vascular complications are major causes of morbidity and mortality in type 2 diabetes patients. Mitochondrial reactive oxygen
species (ROS) generation and a lack of efficient antioxidant machinery, a result of hyperglycaemia, mainly contribute to this
problem. Although advances in therapy have significantly reduced both morbidity and mortality in diabetic individuals, diabetes-
associated vascular complications are still one of the most challenging health problems worldwide. New healing options are
urgently needed as current therapeutics are failing to improve long-term outcomes. Particular effort has recently been devoted to
understanding the functional relationship between chromatin structure regulation and the persistent change in gene expression
which is driven by hyperglycaemia and which accounts for long-lasting diabetic complications. A detailed investigation into
epigenetic chromatin modifications in type 2 diabetes is underway. This will be particularly useful in the design of mechanism-
based therapeutics which interfere with long-lasting activating epigenetics and improve patient outcomes. We herein provide an
overview of the most relevant mechanisms that account for hyperglycaemia-induced changes in chromatin structure; the most
relevant mechanism is called “metabolic memory.”
1. Introduction
Diabetes is a leading cause of morbidity and mortality
across the world [1, 2]. Population age, obesity, and modern
sedentary lifestyles mean that the incidence of type 2 diabetes
(T2D) has significantly increased worldwide in recent years
[2–4]. Type 2 diabetes is associated with long-term vascular
complications, including endothelial dysfunction, atheroscle-
rosis, nephropathy, retinopathy, and peripheral arterial dis-
ease (PAD) [5–8]. Although advances in therapy have led
to a significant reduction in both micro- and macrovascular
complications, overall cardiovascular risk is still a clinical
problem [9–12]. The Diabetes Control and Complications
Trial (DCCT/EDIC) [9, 10] and the UK Prospective Diabetes
Study (UKPDS) [11, 12] have shown that a coupling of
intensive glycaemic control and the close monitoring of both
blood pressure and cholesterol may not be effective in pro-
tecting patients from vascular complications, thus suggesting
that diabetes-associated cardiovascular risk factors may rely
on the so-called “metabolic memory.” “Metabolic memory”
mainly reflects epigenetic changes driven by hyperglycaemia-
induced oxidative stress [13–16]. Attention has so far been
paid to dissecting these epigenetic mechanisms and defining
a diabetes epigenetic signature which would allow new ther-
apeutic approaches, which could “erase” epigenetics and im-
prove patient outcomes, to be developed.This concise review
provides a synopsis of how epigenetic mechanisms impact
long-term diabetes-associated complications.
2. Epigenetic Changes: ROS-Mediated
Effects in Diabetes
Free radical accumulation in the vasculature of diabetic
patients is considered to be the most significant mechanism
in long-lasting vascular complications [17, 18]. The key role
played by mitochondrial ROS generation is a key pathway
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in the natural history of diabetes-associated vascular dis-
ease and has been documented by the seminal studies of
Brownlee and colleagues [18–21]. Similarly, data provided by
El-Osta and colleagues have contributed to current knowl-
edge that links ROS of mitochondrial origin to endothelial
dysfunction [22–24]. More recently, the intimate association
between increased oxidative stress of mitochondrial origin
and defective antioxidantmachinery has been used to explain
pathophysiological pathways associated with a prolonged
response even to transient hyperglycaemia exposure [16,
25]. The fact that this hyperglycaemic environment can be
remembered by the vasculature, first suggested by Roy and
colleagues in 1990 [26], has recently furnished the mecha-
nistic elucidation of what is called “metabolic memory.” As
a matter of fact “metabolic memory” refers to epigenetic
changes driven by hyperglycaemia-mediated mitochondrial
ROS production. The term “epigenetic” was first coined by
Waddington in 1942 to explain how environmental factors
can affect the phenotype without altering the genotype.
Although its conceptual origins date back to Aristotle (384–
322 BC), who believed in “epigenesis” in the development
of an individual organic form from the unformed, traces of
epigenetics were seen in the literature by the mid-nineteenth
century. It currently refers to heritable traits that do notmatch
changes in theDNA sequence.This concept has recently been
cited as a means to explain how the complex interaction
between genotype and environmental cues (hyperglycaemia
in diabetes) brings about “metabolic memory” [13–16, 22–
25]. Long- (heritable) or short-acting (nonheritable) envi-
ronmental cues can lead to long- or short-term epigenetic
effects, respectively. In diabetes, both mechanisms can take
part in reprogramming the epigenome and eventually give
details about the awful “metabolic memory” of postprandial
hyperglycaemia episodes [14, 15, 27]. Over the last few years, a
number of studies have shown that chromatin modification,
in the nucleus, and microRNA (miR) deregulation, in the
cytoplasm, are hallmarks of the long-lasting detrimental
effects of hyperglycaemia which may translate into the high
residual cardiovascular risk that diabetic patients face despite
multifactor intervention [28].
3. Epigenetics in the Nucleus
Chromatin is the form in which the nucleic acids are found
in the cell. Chromatin is, in fact, a macromolecular complex
formed of DNA, proteins (histones), and RNA. Gene tran-
scription is strictly controlled by the dynamic arrangement of
chromatin: transcriptionally active (euchromatin) and tran-
scriptionally inactive (heterochromatin). Histone posttrans-
lational modifications (PTHMs) and DNA methylation both
control gene expression. Changes in chromatin structure as a
result of an imbalance in ROS production is themost relevant
nuclear epigenetic mechanism and accounts for the long-
lasting effects of hyperglycaemia [29–31]. Histones and DNA
are considered to be the foremost targets of epigenetic factors
in this setting [29–31]. PTHM modification alters chromatin
packing and results in different DNA arrangements and read-
outs. The most relevant PTHM changes in diabetes are lysine
acetylation, by histone acetyltransferases (HATs), and lysine
and arginine methylation, by histone methyltransferases
(HMTs) [32]. The acetylation of H3K and H4K terminal tails
generally erases any interaction with DNA, allowing euchro-
matin to form and gene transcription to occur. Conversely,
histone methylation is associated with a more complex and
“capricious” gene transcriptional status [13–16]. Indeed, the
mono-, di-, or trimethylation of various lysine residues in
the H3 tail can cause either transcriptional activation or
repression. Of the enzymes that regulate this process, histone
methyltransferases Set7 and Set9 are the most relevant, are
activated in the hyperglycaemic settings, and mainly control
genes involved in the inflammatory response [33]. Neverthe-
less, as a result of histone acetylation/methylation, a number
of inflammatory genes undergo transcription in response
to hyperglycaemia over time [14, 16, 28]. This sustains
the relevance of such a mechanism in perpetuating tissue
damaging signals in diabetes. Even transient hyperglycaemia
can lead to long-lasting epigenetic changes in the promoter
of the NF-𝜅B-p65 gene, resulting in the increased expression
of its product in the diabetic setting [22, 34]. More recently,
it has been reported that the mitochondrial adaptor protein
p66shc may be transcriptionally regulated by H3 acetylation
[25]. p66shc overexpression and mitochondrial translocation
have been linked to increased mitochondrial ROS genera-
tion, reduced nitric oxide bioavailability, and vascular cell
apoptosis [25]. The biological relevance of H3 acetylation in
p66shc expression was further supported by the observation
that the overexpression of one member of class III histone
deacyltransferase (HDAC) SIRT1 inhibits hyperglycaemia-
induced p66shc expression, improves endothelial function,
and reduces oxidative stress markers [35] A close connection
between p66shc, SIRT1, and tumour transcription factor p53
[25, 36, 37] has been also reported, which supports the crucial
role that the epigenetic mechanism plays in dictating cell
fate, predominantly in the vascular system. p66shc is a good
example of a nuclear epigenetic target as its expression can be
regulated byDNAmethylation aswell [25]. DNAmethylation
depends on three different DNA methyltransferases (DMT1,
DM3A, and DM3B) in mammalian cells [38]. In these cells,
DMT3A and DMT3B provide de novo methylation of the
CpG dinucleotides on cytosine [39]. Therefore, DNA regions
with increasedCpG clusters, also called “CpG islands,” dictate
gene transcription status [40, 41]. The hypermethylation of
CpG islands in the promoter region commonly translates
into transcription repression, while low methylation has
the opposite effect [42]. The fact that DNA methylation
can influence the expression of genes involved in diabetes-
associated complications has been documented in preclinical
models of nephropathy and retinopathy [43, 44]. In addition,
genome-widemethylation studies indicate that 19 prospective
CpG regions are associated with an increased risk of diabetic
nephropathy in type 1 diabetic patients [45]. Finally, studies
performed on peripheral blood cells recovered from patients
participating in the DCCT/EDIC study have demonstrated
a correlation between chronic complications and H3K9
acetylation [46].
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4. Epigenetics Regulated by
Cytoplasmic Factors
In addition to DNA methylation and histone modifications,
microRNAs (miRs) have emerged as relevant epigenetic reg-
ulators. miRs are a class of noncoding sequences which reg-
ulate gene expression at the posttranscriptional level via the
inhibition of ribosome function, resulting in the translational
repression or degradation of the targetmRNA [47]. Although
miRsmost commonly lead to decreased gene expression, they
can also induce gene upregulation by negatively modulating
the expression of inhibitory genes. However, miR downregu-
lation may also upregulate previously suppressed genes [47–
49]. More importantly, single miR targets multiple genes
while single genes can be regulated by several miRs [47–49].
A number of studies demonstrating that miR expression is
tissue specific have suggested that miRs may be important
to establish and maintain cell type and tissue identity [49–
53]. However, in recent years their role in mediating chronic
diseases has been deeply investigated. As a matter of fact,
abnormal miR levels have been described in clinical and
preclinical models of diabetes-associated complications [54,
55]. The role of miRs in diabetic nephropathy (DN) has
been extensively studied. Altered levels ofmiR25- andmiR21-
driven posttranscriptional regulation of the NADPH-oxidase
subunits NOX4 and PTEN, respectively, have been linked
to diabetic nephropathy in rat and mouse models [56, 57].
Moreover, Wang and colleagues [58] demonstrated that the
treatment of proximal-tubular epithelial cells with TGF-𝛽1
and TGF-𝛽2 led to miR-141 and miR-200a downregulation.
The overexpression of miR-200a was found to be associated
with the posttranscriptional regulation of TGF-𝛽2 which
is consistent with miR-200a’s role in the development and
progression of TGF-𝛽-dependent kidney fibrosis [58]. Sim-
ilarly, increased miR-377 levels contributed to fibronectin
production and kidney fibrosis in human and mouse mesan-
gial cells that were exposed to TGF-𝛽 and hyperglycemia
[59]. Furthermore, kidney specific miR-192 knockdown was
found to provide protection against diabetic nephropathy-
associated kidney fibrosis [60].
Several miRs have been associated with the early stages
of diabetic retinopathy (DR) development as well as disease
progression. An evaluation of retinal endothelial cells and
diabetic retinas indicated that numerous different targets
were involved in angiogenesis, inflammation, and oxidative
stress. Feng et al. [61] demonstrated that both endothelial
cells from large vessels and retinal microvessels that had been
treated with high glucose content express high fibronectin
(FN) levels bymeans ofmiR-146a downregulation.Moreover,
they also show that miR-200b controls miR-146a and FN
expression, via the histone acetylator p300, in hyperglycemic
conditions not only in the retina but also in the heart and
kidney.
Recent data indicate that the reality is more complicated
than expected as othermiRs are involved inHDACregulation
[62]. Indeed, it has been reported that miR-29 and miR206
overexpression leads to HDAC4 translational repression
during myogenic differentiation [63]. Furthermore, Lin et al.
[64] demonstrated that hyperglycemia contributes to nephrin
acetylation and renal dysfunction by impairing miR-29a
signalingwhich resulted in improvedHDAC4 action.Various
miRs, including miR1, miR206, miR133a, miR221/222, and
miR126, have also been implicated in cardiovascular com-
plications as they act on various targets in cardiomyocytes
and vascular cells [17, 65–67], while cardiac microvascular
endothelial cells were found to express high miR-320 levels
in a preclinical model of type 2 diabetes [68].
Although not as intensely investigated, unbalanced ROS
production was found to be involved in miR deregulation
[69]. In this regard, we have recently reported that interfer-
ing with mechanisms involved in ROS production rescues
miR126 expression and reverts the epigenetic pattern in
endothelial cells [70]. Indeed, we were able to reprogram
some epigenetic abnormalities, such as SIRT1 expression and
p53 and H3K56 acetylation status, in ob/ob mice subjected
to peripheral artery disease by administering the naturally
occurring hormone, unacylated ghrelin (UnAG) [70]. As
this effect translates into hind limb function improvement,
the notion of epigenome reprogramming being able to offer
clinical benefits in a diabetic setting is strengthened.
5. An Epigenomic Fingerprint for Identifying
High-Risk Diabetic Patients
As stated above, the epigenome refers to DNA methylation,
histonemodification, and chromatin accessibility throughout
the genome. Each cell type possesses a unique epigenome,
which defines its regulatory program, and each individual
displays unique epigenome modifications [71, 72]. It has
been extensively demonstrated that exposure to environ-
mental cues affects an individual via their own epigenome.
It has therefore become clear that an understanding of
how genetic, epigenetic, and environmental factors interact
with each other to drive chronic disease development and
progression is mandatory [14, 15, 27, 28, 73]. Advances in
genome-wide technologies and bioinformatics have opened
up new possibilities in recent years [74, 75]. The use of chip-
sequencing to map several histone and DNA methylation
marks has demonstrated that changes in DNA methylation
patterns and histone modification are crucial for genetic
information readout [76]. A genome-wide map of epigenetic
modifications across several pathologic conditions, including
diabetes, would therefore be particularly relevant in thera-
peutic target identification. The Human Epigenome Project,
established in 1999, identifies and interprets genome-wide
DNA methylation patterns in human genes. It is therefore
widely expected that an exact and detailed map of epige-
netic variations may allow scientists to better understand
epigenetic biogenesis and function and further improve gene-
based treatment as well as preventing diabetic complications.
In this sense, epigenomic analysis in human pancreatic
islets shows a strict association with gene expression and
histone modification and is possibly relevant to diabetes [77].
More recently, data from Nilsson et al. [78] have provided
support for the role played by DNA methylation in modu-
lating the expression of genes associated with discrete path-
ways that are causally involved in T2D, thus strengthening
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Figure 1: Schematic representation of epigenetic mechanisms in diabetic setting. In the nucleus ROS-mediated histone acetylation/meth-
ylation as well as DNAmethylation accounts for gene transcriptional activation or repression. In the cytoplasmROS-mediated changes inmiR
expression drive posttranscriptional regulation of target genes. Such epigenetic changes impact long-term diabetes-associated complications.
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the notion that genetics, epigenetics, and environment cues
may alsomutually contribute to type 2 diabetes susceptibility.
A challenge for the future thus lies in using next-generation
sequencing techniques, such as RNA-sequencing and whole-
genome sequencing, to identify the gene-expression regula-
tory network associated with high-risk diabetic patients on
the DNA level.
6. Pharmacological Reprogramming of
the Epigenome: A Novel Therapeutic Option
A detailed characterization of deranged gene expression
patterns in diabetes has pulled clinicians towards epigenetic
reprogramming approaches. A number of preclinical studies
have indicated that gene expression can be modulated by
treatment which interferes with the acetylation and methy-
lation of histone/DNA complexes [16, 28]. As a matter of
fact, folate treatment can affect the expression of genes
regulated by CpG methylation by reducing homocysteine
[79]. p66shc is one of the genes regulated by CpGmethylation
in response to homocysteine [80]. A complete exploration
of the potential clinical applications of folate is therefore
an interesting challenge for the future. Other therapeutic
epigenome-based options have been proposed; however,
potential clinical application is still being debated. A reason
for this was the failure of resveratrol, which was originally
described as a potent SIRT1 activator that was able to rescue
NObioavailability [81] and increase p66shc promoter deacety-
lation [35], to provide beneficial effects when supplemented
in obese patients [82]. A number of preclinical studies have
also been performed on metformin, which is currently used
to treat diabetic patients and which is known to increase
SIRT1 expression and suppressNF-𝜅B activation [37]. Indeed,
it has been shown that metformin is effective in suppressing
the deleterious effects of hyperglycaemia in retinal capillary
endothelial cells and in the retinas of diabetic animals by
modulating the SIRT-1/LKB1/AMPK pathway [37]. However,
the early enthusiasm for this drug that acts in the metabolism
is in stark contrast with the controversial results obtained
in UKPDS and Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trials, where metformin treatment led
to reduced cardiovascular events in the first and an increased
occurrence of these events in the second. Finally, the use of
curcumin, known to exert beneficial effects by acting on the
histone acetylator p300, has been proposed. However, even
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curcumin failed to be successful and the authors suggest that
curcumin finds use as an adjuvant therapy in type 2 diabetic
patients [83].
While the removal of epigenetic tags appears to be
crucial in improving diabetes patient outcomes, clinical study
results are far from convincing. It is, however, always worth
remembering that the number of trials and the patients
included in them is still a source of major bias when
attempting to obtain persuasive results. This implies that
effort should be made to assess the “true” clinical efficacy
of the above compounds in randomized controlled trials.
Moreover, genome-wide analysis of DNA methylation and
histonemodifications may well be the tool of the future when
exploring new “personalized signature” based therapeutics.
7. Conclusions and Perspectives
Increased ROS of mitochondrial origin and defective mito-
chondrial electron transfer chains appear to be the most
relevant mechanisms in what is known as “metabolic mem-
ory.” “Metabolic memory,” which refers to the effects of
hyperglycaemia on long-term vascular complications,mainly
relies on changes in chromatin structures andmiR expression
(Figure 1) [28]. Over the last few years, more details on
how hyperglycaemia drives changes in the epigenome have
been provided and a putative epigenome signature has been
proposed. Moreover, genome-wide methylation studies have
indicated that epigenetic mechanisms can predict nephropa-
thy in type 1 diabetic patients [45].Thus, future efforts should
be directed towards clinically exploiting the epigenome
signature so as to identify patients with a high risk of
complications and epigenome targeting approaches. Indeed,
recent efforts have been directed towards developing agents
which are able to reprogram the epigenome and hamper the
vicious hyperglycaemia driven circle which leads to residual
cardiovascular risk in diabetic patients [84]. However, it is
always worth remembering that since environmental factors
are the main triggers of epigenetic modifications, a suitable
lifestyle should be recommended above all other factors.
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